{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(18)"],"submitter":["Vempati R"],"pubmed_abstract":["<b>Background:</b> Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, increasingly prevalent worldwide. Type 2 diabetes mellitus (T2DM) is a major chronic disorder and a significant risk factor for AF, contributing to high morbidity and mortality. Metformin monotherapy can contribute to the reduced occurrence of adverse cardiovascular outcomes in patients with T2DM, but its effects on AF are understudied. This meta-analysis evaluates the association of metformin with the risk of incident AF among patients with T2DM on metformin. <b>Methods:</b> Databases, including PubMed, Google Scholar, and EMBASE, were screened through November 2024 for studies evaluating the association between metformin and new-onset AF in patients with T2DM. Comprehensive Meta-Analysis (CMA) ve"],"journal":["Diagnostics (Basel, Switzerland)"],"pagination":["2288"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12468145"],"repository":["biostudies-literature"],"pubmed_title":["Metformin and Risk of New-Onset Atrial Fibrillation in Type 2 Diabetes: A Systematic Review and Meta-Analysis."],"pmcid":["PMC12468145"],"pubmed_authors":["Reguram R","Vempati R","Mylavarapu M","Vasudevan SS","Krishnamoorthy G","Damarlapally N","Jain H","Roy P","Ahmed R","Vora T"],"additional_accession":[]},"is_claimable":false,"name":"Metformin and Risk of New-Onset Atrial Fibrillation in Type 2 Diabetes: A Systematic Review and Meta-Analysis.","description":"<b>Background:</b> Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, increasingly prevalent worldwide. Type 2 diabetes mellitus (T2DM) is a major chronic disorder and a significant risk factor for AF, contributing to high morbidity and mortality. Metformin monotherapy can contribute to the reduced occurrence of adverse cardiovascular outcomes in patients with T2DM, but its effects on AF are understudied. This meta-analysis evaluates the association of metformin with the risk of incident AF among patients with T2DM on metformin. <b>Methods:</b> Databases, including PubMed, Google Scholar, and EMBASE, were screened through November 2024 for studies evaluating the association between metformin and new-onset AF in patients with T2DM. Comprehensive Meta-Analysis (CMA) ve","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-05-02T03:11:43.062Z","creation":"2026-05-02T03:07:49.371Z"},"accession":"S-EPMC12468145","cross_references":{"pubmed":["41008660"],"doi":["10.3390/diagnostics15182288"]}}